Celecoxib in Treating Patients With Bladder Cancer

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Recurrent Bladder Cancer

In brief

This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer

Key facts

Study ID

NCT00006124

Run by

National Cancer Institute (NCI)

People needed

152

Starts

2000-06-01

Expected to finish

2008-04-01

Last updated by the study team

2013-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.